Suven Life Sciences Limited has issued a formal clarification to BSE Limited addressing recent price movements in its stock. The communication, dated February 6, 2026, was submitted in response to BSE's surveillance inquiry regarding unusual price activity.

Company's Response to BSE Surveillance

The pharmaceutical company clarified its position through a detailed response to BSE's surveillance department. The clarification was prompted by BSE's inquiry reference L/SURV/ONL/PV/AJ/ 2025-2026 / 3355 dated February 5, 2026.

Regulatory Compliance Statement

Suven Life Sciences emphasized its commitment to regulatory compliance, stating that the company has been consistently notifying stock exchanges of all material events and information falling under Regulation 30 of SEBI (LODR) Regulations, 2015. The company maintained that it follows proper disclosure protocols for all significant developments.

The management confirmed that no material announcements or events are currently pending notification to stock exchanges under SEBI regulations that could influence the stock's price or volume behavior.

Market Speculation Attribution

The company attributed recent price and volume movements to market speculation rather than any undisclosed material information. Suven Life Sciences stated it has no additional comments regarding the recent market developments affecting its stock performance.

The clarification has been made available to the general public through dissemination on BSE's website and the company's official website, ensuring transparency in communication with stakeholders.

Suven Life Sciences Limited announced major corporate developments following its board meeting held on January 29, 2026, including equity share allotment and key management personnel changes. The pharmaceutical company's board approved significant capital restructuring alongside leadership transitions in compliance with regulatory requirements.

Equity Share Allotment Through Warrant Conversion

The board approved the conversion of 44,77,612 fully paid warrants into equity shares, resulting in the allotment of an equal number of equity shares to non-promoter entities. The shares were issued at Rs 134 per share on a preferential basis, generating total proceeds of Rs 60,00,00,008.

The allotment was conducted in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, with the company receiving 100% consideration from the allottees. Each equity share carries a face value of Rs 1 with a premium of Rs 133 per share.

Impact on Share Capital Structure

Following the preferential allotment, Suven Life Sciences' paid-up equity share capital witnessed substantial expansion. The conversion resulted in a notable increase in the company's equity base.

Company Secretary Resignation

Mr. Shrenik Soni tendered his resignation from the position of Company Secretary and Compliance Officer, effective from close of business hours on January 30, 2026. The resignation was submitted on November 11, 2025, citing pursuit of alternate career opportunities as the primary reason, with no other material factors involved.

The board accepted the resignation and recorded appreciation for Mr. Soni's services during his tenure. His departure necessitated immediate succession planning to ensure continuity in statutory compliance functions.

New Company Secretary Appointment

Ms. Sangeetha Laxmi Kandari has been appointed as the new Company Secretary and Compliance Officer, taking charge from February 2, 2026. The appointment was made based on recommendations from the Nomination and Remuneration Committee.

Ms. Kandari brings extensive experience in corporate, secretarial, and compliance functions, having previously worked with Shilpa Biocare Pvt. Ltd, Avra Laboratories Pvt. Ltd, and Prasad Media Corporation Pvt. Ltd. She will also serve as Compliance Officer under SEBI (LODR) Regulations and SEBI (PIT) Regulations, 2015.

Board Meeting Details

The board meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST on January 29, 2026. All decisions were made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with appropriate disclosures submitted to stock exchanges.